Crescent Biopharma holder plans $33K share sale

CRESCENT BIOPHARMA, INC.

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. (CBIO) is the issuer for which a Form 144 notice has been filed relating to planned sales of its ordinary shares by Joshua T. Brumm. The notice lists 1,771 ordinary shares to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $33,294.80 as of September 16, 2026, on Nasdaq.

The filing also notes 3,444 ordinary shares underlying restricted stock units scheduled to vest on September 15, 2026, as compensation for services rendered by the issuer, and discloses that 42,305 ordinary shares were sold during the prior three months on June 22, 2026 for $761,257.32. The notice is signed on behalf of Brumm by Barbara Bispham Hale as Attorney-in-Fact.

Key Figures

Planned shares to be sold: 1,771 ordinary shares Aggregate market value of planned sale: $33,294.80 RSU-related shares: 3,444 ordinary shares +2 more

5 metrics

Planned shares to be sold 1,771 ordinary shares Ordinary shares of Crescent Biopharma, Inc. to be sold under Form 144

Aggregate market value of planned sale $33,294.80 Market value of 1,771 ordinary shares as of September 16, 2026

RSU-related shares 3,444 ordinary shares Shares underlying restricted stock unit vesting on September 15, 2026 for services rendered

Shares sold in past 3 months 42,305 ordinary shares Ordinary shares sold by Joshua T. Brumm on June 22, 2026

Proceeds from prior sale $761,257.32 Aggregate sale price for 42,305 ordinary shares sold June 22, 2026

Key Terms

Rule 144, Restricted Stock Unit Vesting, Attorney-in-Fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Unit Vesting financial

"Ordinary Shares | 09/15/2026 | Restricted Stock Unit Vesting | Issuer"

Attorney-in-Fact regulatory

"Signature | /s/ Barbara Bispham Hale, as Attorney-in-Fact for Joshua T Brumm"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for CBIO disclose about planned share sales?

The Form 144 for CBIO discloses that Joshua T. Brumm plans to sell 1,771 ordinary shares of Crescent Biopharma, Inc. through Morgan Stanley Smith Barney LLC, with an aggregate market value of $33,294.80 based on the September 16, 2026 market price.

Who is selling Crescent Biopharma (CBIO) shares under this Form 144?

The seller identified is Joshua T. Brumm. The notice states that the securities are to be sold for his account under Rule 144, and it is signed on his behalf by Barbara Bispham Hale as Attorney-in-Fact.

How many CBIO shares has Joshua T. Brumm sold in the last three months?

The notice reports that during the past three months Joshua T. Brumm sold 42,305 ordinary shares of Crescent Biopharma, Inc. on June 22, 2026 for an aggregate sale price of $761,257.32.

What restricted stock unit vesting is disclosed for CBIO in this Form 144?

The filing lists 3,444 ordinary shares tied to restricted stock unit vesting on September 15, 2026. These shares are shown as issued by the company to Joshua T. Brumm for services rendered.

Through which broker are the planned CBIO share sales to be executed?

The Form 144 indicates that the 1,771 ordinary shares of Crescent Biopharma, Inc. are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, New York.

On which market are the CBIO shares in this Form 144 expected to trade?

The notice states that the ordinary shares of Crescent Biopharma, Inc. to be sold under this Form 144 are listed for trading on Nasdaq as of September 16, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 03:09 PM Accepted by SEC EDGAR 09/16/2026 - 03:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001528826
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Crescent Biopharma, Inc.
SEC File Number	001-36177
Address of Issuer	300 5th Ave Waltham MASSACHUSETTS 02451
Phone	6174305595
Name of Person for Whose Account the Securities are To Be Sold	Joshua T Brumm
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1771	33294.8	37143940	09/16/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	09/15/2026	Restricted Stock Unit Vesting	Issuer			3444	09/15/2026	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joshua T Brumm 300 5th Ave Waltham MA 02451	Ordinary Shares	06/22/2026	42305	761257.32

144: Remarks and Signature

Remarks	Exhibit List - Exhibit 24 - Power of Attorney
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Barbara Bispham Hale, as Attorney-in-Fact for Joshua T Brumm
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)